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Abstract: Background: There are indications that mortality in breast cancer is related with dietary factors, but no study 
has been large enough to characterise reliably how, this risk is influenced. To establish a logistic regression equation that 
would predict breast cancer from factors in the endocrinological and metabolic profile, we studied endocrinological and 
metabolic risk factors that are modified by the diet, in a population of women with breast cancer in southern Spain. 
Patients and Methods: We carried out a simple a case-control study comparing 204 women with breast cancer (96 
premenopausal and 108 postmenopausal women) and 250 healthy control subjects. The predictive variables were basal 
glycaemia, insulin, glycosylated haemoglobin (HbA1c), C-peptide, insulin-like growth factor-I (IGF-I), total cholesterol, 
triglycerides, high density lipoprotein-c (HDL-C), low density lipoprotein-c (LDL-C), selenium and Quetelet index 
(BMI).  
Results: The metabolic profile differed between pre- and postmenopausal patients, and metabolic alterations were greater 
in postmenopausal than in premenopausal women. The differences between healthy subjects and breast cancer patients 
were clearly significant. 
Conclusions: Our findings have several potential practical applications in the early detection of breast cancer, especially 
in premenopausal women; in primary prevention; and in the development of a mathematical model of breast carcinogene-
sis.  
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INTRODUCTION 
  Breast carcinoma includes a heterogeneous group of tu-
mors with variable prognosis. International rates of breast 
cancer between countries suggests that environmental fac-
tors, perhaps dietary, may influence the risk of this disease. 
We investigated some endocrine and metabolic factors influ-
enced by diet to establish profile of breast cancer. In Spain, 
incidence of breast cancer increased is 2.26 times the mortal-
ity from this tumour [1] and mortality from breast cancer 
increased 122% in absolute terms (62% adjusted rate) from 
1961 to 1980 [2]. It are look at the changes in Spain during 
this period in comparison with the preceding years it shows 
that socioeconomic level increased significantly, and so did 
food availability and consumption [3]. During the same pe-
riod there was a clear decrease in mortality from stomach 
cancer [4]. Decreasing mortality by gastric cancer showed a 
significant inverse correlation with mortality from breast 
cancer and quantitative variations in the diet with time, and 
differences in the diet between regions; in fact, mortality 
from breast cancer was significantly greater in coastal than in 
inland provinces and the contrary was happening with stom-
ach cancer: the link between both is diet [4-6].  
  We have found that although menarche occurs one year 
later in northern than in southern Spain (because of the geo-
graphical influence of latitude), mortality from breast cancer 
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is much higher in the former than in the latter part of the 
country [6]. Women who became obese as adults, the degree 
of obesity was inversely related with age at menarche: the 
greater the Quetelet index in adulthood, the younger the age 
at menarche [7]. This finding suggests that early menarche is 
not a primary risk factor for breast cancer, but is rather a 
consequence of the increasing socioeconomic level in Spain 
and the diet [3]. The epidemiological evidence of an associa-
tion between dietary fat and the development of breast can-
cer is strong and is supported by numerous animal models. 
Several studies have identified an association between in-
creasing body mass index and advanced stage breast cancer 
[8].  
  Postmenopausal women with breast cancer were found to 
have a significant degree of relative hyperglycaemia; al-
though basal glycaemia was within the normal range, the 
values were higher than in normal control subjects [8]. 
Moreover, insulin levels and C-peptide values [9] correlated 
directly with basal glycaemia [10]. Blood glucose concentra-
tions vary widely through a 24 hours period, and HbA1c is 
used as a more accurate measure of these daily variations 
[11]. According to Jackson et al. insulin-like growth factor I 
(IGF-I) have clearly defined mitogenic effect on mammary 
cancer cells and it is possible that they promote carcinogene-
sis in human mammary tissue, protecting cells from apopto-
sis and enhance metastasis [12]. Hankinson et al. reported 
that high circulation IGF-I concentrations would be associ-
ated with an increased risk of breast cancer patients [13].  2    The Open Clinical Cancer Journal, 2008, Volume 8  Lopez-Saez et al. 
  Electrocardiography studies of the prevalence of cardiac 
insufficiency in 512 women with breast cancer revealed a 
significant increase in signs of coronary insufficiency in 
these patients in comparison with healthy control subjects, 
these observations suggest, a possible relation between coro-
nary atherosclerosis and breast cancer [14].  
  Angiotensin-converting enzyme (ACE) activity was also 
investigated in patients with breast cancer and was elevated 
in women in complete remission in both cases comparing the 
values with normal controls [15].  
 Zielinski  et al. found a relative increase in serum total 
cholesterol in patients with breast cancer [16]. HDL-C levels 
are also influenced by diet. Because this factor has been little 
studied in breast cancer patients [17]. We searched for possi-
ble relationships between HDL-C levels and breast cancer. 
  The relation between selenium and the etiology of cancer 
in humans remains elusive and intriguing, despite the num-
ber of epidemiologic studies published on the topic. Low 
levels of selenium have been associated with a higher risk of 
cardiovascular diseases and cancer in humans, which is an-
other important factor related to dietary intake [18]. This 
element has been shown to be decreased in women with 
breast cancer [19]. The effects of the insulin as a cellular 
growth factor is partly mediated by the IGF-I [20]. The In-
ternational Agency for Research on Cancer (IARC) and 
other cancer research organisations periodically publish list 
of human carcinogens [21].  
  In this article, we analyse some arguments that support 
the important effect of diet on breast carcinogenesis and 
metabolic and endocrine parameters that are modified by 
diet. 
  The aim of the present study was therefore to develop a 
logistic regression equation that would predict a diagnosis of 
breast cancer on the basis of metabolic parameters, selecting 
a combinations of variables with the best sensitivity and 
specificity. Evidence from population-based studies might 
suggest reliable biomarkers of breast cancer risk among con-
ventional clinical variables, that could provide a strategy for 
identifying high-risk individuals who might benefit from 
preventive intervention. 
PATIENTS AND METHODS 
Study Design 
  A simple case-control study reported here was designed 
to search for a possible relation between endocrine and 
metabolic parameters and the likelihood of breast cancer. We 
compared the values for these parameters in patients and 
healthy controls in pre- and postmenopausal women. Vari-
ables that differed significantly between patients and con-
trols were included in a mathematical model used to calcu-
late the probability of a diagnosis of breast cancer.  
Participants 
  We identified 215 women who had been diagnosed with 
breast cancer admitted to any of the hospitals in which such 
patients were treated. Of the original sample, 204 were eligi-
ble cases (96 pre- and 108 postmenopausal patients). The 
mean age was 52 years (range: 32-80). Reasons for exclusion 
being: diagnosis not confirmed by histopathology [6], ad-
vanced stage at time of diagnosis [3], or patient’s refusal [2]. 
We included women who had been operated on recently, 
women whose disease was in prolonged clinical remission, 
and women with just detected active recurrence that had not 
yet been treated with chemotherapy/hormotherapy/inmmu-
notherapy/radiotherapy. All the cases were ductal infiltrating 
carcinoma, classified according to the World Health Organi-
sation classification of breast tumours (WHO) [22].  
  Control subjects, ascertained in the same time period, 
were randomised of the population residing in each of the 
areas. 250 apparently healthy women (with no clinical or 
mammography evidence of malignancy in the breast), of the 
same age group and share the same environmental were se-
lected. All cases with advanced or recently treated disease or 
carriers of the other chronic disease, included arterial hyper-
tension, psychiatric disease, congestive heart failure, diabetes 
mellitus and who were using hormone-replacement therapy 
(HRT) or tamoxifen were excluded. The outcome variable 
considered was patient/control status. Patients were defined 
as women with histologically confirmed breast cancer; con-
trols were defined as apparently healthy, asymptomatic 
women. Menopausal status was defined at the moment of 
blood collection. A premenopausal woman was defined if 
she had at least one natural cycle in the previous 12 months 
or was younger than 48 years or after hysterectomy. A post-
menopausal woman was defined if she reported a natural 
menopause or bilateral oophorectomy, or if she was at least 
56 years. All individuals had normal thyroid-function, be-
cause the thyroid function might change after treatment for 
breast cancer, especially after irradiation of the purposes of 
logistic regression analysis, this qualitative variable was used 
quantitatively (patient=1, control=0).  
  All subjects were recruited from the University Hospital 
of Puerto Real or Misericordia Hospital (Cádiz, Spain), dur-
ing the period from February 1, 2004 to November 31, 2006. 
All participants gave their informed consent to take part in 
the study, the protocol was approved by the Ethic Committee 
of Hospital, which was done in accordance with the recom-
mendations of the Declaration of Helsinki.  
Clinical Parameters and Laboratory Procedures 
  Variables that might potentially predict disease were se-
lected if they were known to be related with diet, and if they 
varied (or could be expected to vary) with tumour status: 
basal blood levels of glucose, insulin, HbA1c, C-peptide, 
IGF-I, total cholesterol, triglycerides, HDL-C, LDL-C, sele-
nium, and BMI. All values were treated as numerical con-
tinuous variables. The prediction variables were selected by 
their dependency on diet and variations with tumoral status. 
From the initial model, including all variables, were elimi-
nated one by one until they get the model with the best sensi-
tivity and specificity. 
  Body weight was measured to the nearest 0.2 kilograms 
with participants dressed in lightweight clothing, and height 
was measured to the nearest < 0.5 centimeters after the sub-
ject shoes had been removed. BMI was calculated with the 
formula BMI=body weight/height
2. Peripheral blood samples 
were obtained from the subjects fasted for 10-12 h before 
sample collection. A further 10 mL was collected in bottles 
and promptly transported to the laboratory at 4º C for imme-
diate processing. Others aliquots of the sera were stored at –Metabolic Profile of Breast Cancer  The Open Clinical Cancer Journal, 2008, Volume 2    3 
20ºC in a storage freezer, which was not in daily use, until 
analysis. All determinations were carried out whitin a year 
and a half after sample collection. 
  Basal glucose and the concentration of total cholesterol 
and triglycerides were estimated enzymatically [23]. HDL-C 
was assayed enzymatically after precipitation of lipoproteins 
with a density of less than 1.063 g/mL by the addition of 
heparin and MnCl2, according to the method of Warnick 
[24]. LDL-C was calculated according to the Friedewald 
formula [23]. Basal insulin [25] and C-peptide [26] were 
measured with ELISA in the same sample. HbA1c was de-
termined with the specific liquid chromatography technique 
described by Davis [27], IGF-I by RIA [28], and selenium by 
atomic absorption spectrophotometry in a graphite chamber 
[29].  
Statistical Analyses 
  Statistical analysis was performed using the Systat statis-
tical software package [30] run on an IBM-compatible per-
sonal computer. Descriptive analyses were used for all quan-
titative variables. The results for the patient and control 
groups were compared with the Kruskal-Wallis test. Possible 
correlations between different variables were also sought and 
a logistic regression analysis was used: variables were tested 
and excluded until the most sensitive and specific model was 
obtained [31].  
RESULTS 
  Baseline characteristics of the cases and controls, by 
years, menopausal status, are shown in Table 1. The results 
for pre- and postmenopausal women were analysed sepa-
rately. In premenopausal women, significant differences 
were found between patients and control subjects in HbA1c 
level (p<0.001), insulin concentration (p=0.030), C-peptide 
concentration (p=0.004), IGF-I (p<0.001), total cholesterol 
(p<0.001) and selenium (p=0.002) (Table 2). Among post-
menopausal women, patients with breast cancer and healthy 
control subjects differed significantly in basal glycaemia 
(p<0.001), HbA1c level (p=0.008), C-peptide concentration 
(p<0.001), total cholesterol (p<0.001), HDL-C (p<0.05), 
LDL-C (p<0.05), selenium (p<0.001) and BMI (p=0.101) 
(Table 3).  
Table 1.  Baseline Characteristics 
VARIABLES CONTROLS  N=250 CASES  N=204 
Premenopausal women  125 108 
Age (years)  39.6  40.3 
Age at menarche (years)  12.1  12.7 
Postmenopausal women  125 96 
Age (years)  62.5  62.9 
Age at menopause (years)  47.2  48.0 
Age at menarche (years)  12.6  12.8 
 
Table 2.  Metabolic and Endocrine Parameters in a Sample of Premenopausal Women in Southern Spain 
VARIABLES CONTROLS  (Means)  CI (95%)  PATIENTS (Means)  CI (95%)  P Value 
GLYCEMIE (mmol/L)  5.04 4-6  5.50  5-5.93  =  0.294 
HbA1c (%)  6.47 5-7  7.75  6.99-7.89  <  0.001 
INSULIN (mmol/L)  80.93 78-82  67.01  66.30-68.01  =  0.030 
C-PEPTIDE (mmol/L)  1.86 1.87-1.89  2.59  2.54-2.62  =  0.004 
IGF-I (kU/L)  0.475 0.462-0.480  0.792  0.788-0.801  <  0.001 
CHOLESTEROL (mmol/L)  4.35 4-5.02  6.07  5.09-6.32  <  0.001 
TRIGLYCERIDES (mmol/L)  1.26 1.01-1.33  1.38  1.34-1.42  <0.05 
HDL-C (mmol/L)  3.56 3.42-3.61  3.51  3.48-3.55  <0.05 
LDL-C (mmol/L)  3.48 3.39-3.61  3.51  3.47-3.55  <0.05 
SELENIUM (μg/L)  92.53 90-94  80.21  79.05-81.23  =  0.002 
BMI  25.99 24-27  27.93  26.09-28.03  =  0.115 4    The Open Clinical Cancer Journal, 2008, Volume 8  Lopez-Saez et al. 
Logistic Regression Model for the Diagnosis of Breast 
Cancer in Premenopausal Women 
  The diet-related factors investigated here were tested by 
elimination to determine those which yielded an equation 
with maximal sensitivity and specificity. The variables in-
cluded in the final equation were basal blood concentrations 
of glucose, insulin, C-peptide, HbA1c, IGF-I, total choles-
terol, HDL-C, LDL-C, triglycerides, selenium, and BMI. 
The resulting linear mathematical model predicted the diag-
nosis with a sensitivity of 100% and a specificity of 100%. 
The model is the following: Diagnost=Constant + Gly X1+ 
Insulin X2 + C-pep X3+ HbA1c X4 + IGF-I X5 + Chol X6 + 
HDL-c X7 + LDL-c X8 + Try X9 + Sel X10. 
  The log likelihood of the constants only model was LL(0) 
= -35.341 and 2*[LL(N) - LL(0)] = 70.668; 10 d.f.; chi-
squared p = 0.000; McFadden rho-squared = 1.000.  
Logistic Regression Model for the Diagnosis of Breast 
Cancer in Postmenopausal Women 
  The variables selected by elimination for inclusion in the 
linear model proposed to predict the diagnosis of breast can-
cer were basal blood concentrations of insulin, C-peptide, 
HbA1c, IGF-I, cholesterol and BMI. The resulting linear 
mathematical model predicted the diagnosis with a sensitiv-
ity of 100% and a specificity of 100%. The model is the fol-
lowing: Diagnost= Constant + Insulin X1 + C-pep X2+ 
HbA1c X3 + IGF-I X4 + Chol X5 + BMI X6 . The log like-
lihood of the constants only model was LL(0)=-33.271 and 
2*[LL(N)-LL(0)] = 66.533; 6 d.f.; chi-squared p=0.000; 
McFadden rho-squared=1.000.  
  In both cases of pre and postmenopausal women, the 
model coefficients are the odds ratio calculated by the Systat 
statistical package; but in this study they would be not sig-
nificant.  
DISCUSSION 
  To our knowledge this is the first study to develop a lin-
ear binary logistic regression model that is highly sensitive 
and specific in predicting the diagnosis of breast cancer from 
the subject's endocrine and metabolic profile. All the vari-
ables examined here are clearly modified by the disease and 
with the exception of selenium, the changes resembling 
those found in subjects on a hypercaloric diet. The metabolic 
profile differed clearly in pre- and postmenopausal women: 
nevertheless we identified some variables that predicted the 
likelihood of breast cancer in both of these groups. These 
differences are the reason of two separate models for pre and 
postmenopausal women.  
  Metabolic alterations were greater in postmenopausal 
patients, and highly significant differences between healthy 
control women and patients with breast cancer were found in 
basal concentrations of glucose, HbA1c, C-peptide, total 
cholesterol, selenium and in the Quetelet index. The differ-
ence between these groups approached significance for insu-
lin, IGF-I and triglycerides concentrations, with a bigger 
sample size of future study, this shall be corrected.  
  In premenopausal women the difference in basal glucose 
concentration between patients and controls was not signifi-
cant; in contrast, significant differences were found for gly-
cosylated haemoglobin, serum insulin, C-peptide, IGF-I, 
total cholesterol and selenium.  
  Elevated glycosylated haemoglobin is a more objective 
measure of fluctuating glucose levels than is basal glucose 
concentration, which depends to some extent on the time of 
day when blood is withdrawn. 
  In postmenopausal women the difference in basal glucose 
levels between control subjects and patient was significant; 
however, the difference in insulin levels was not (p=0.076). 
We draw attention to the finding that in both pre- and post-
menopausal breast cancer patients, C-peptide was signifi-
cantly elevated; consequently, insulin hyperproduction oc-
curred. However, serum insulin concentrations were lower in 
both patient subgroups than in their respective control sub-
groups; the difference was significant in premenopausal 
women, and approached significance in postmenopausal 
patients. 
Table 3.  Metabolic and Endocrine Parameters in a Sample of Postmenopausal Women in Southern SPAIN 
VARIABLES  CONTROLS(Means)  CI (95%)  PATIENTS (Means)  CI (95%)  P value 
GLYCEMIE (mmol/L)  4.99 4.59-5.02  6.04  5.99-6.32  <  0.001 
HbA1c (mmo/L)  6.77 6.02-6.96  7.91  7.02-8.25  =  0.008 
INSULIN (mmol/L)  80.93 78.3-81.54  73.4  72.45-74.51  =  0.076 
C-PEPTIDE (mmol/L)  2.06 1.99-2.56  3.54  2.99-3.69  <  0.001 
IGF-I (kU/L)  0.525 0.500-0.563  0.71  0.66-0.75  =  0.079 
CHOLESTEROL (mmol/L)  4.37 4.01-4.87  5.69  5.05-6.31  <  0.001 
TRIGLYCERIDES (mmol/L)  1.31 1.29-1.32  1.65  1.60-1.72  <0.05 
HDL-C (mmol/L)  1.60 1.56-1.68  1.48  1.46-1.52  <0.05 
LDL-C (mmol/L)  3.34 3.30-4.1  4.03  3.99-4.56  >0.05 
SELENIUM (μg/L)  89.79 88.63-90.3  75.16  74.69-75.99  <  0.001 
BMI  25.61 24-26  26.85  24.36-27.12  =  0.010 Metabolic Profile of Breast Cancer  The Open Clinical Cancer Journal, 2008, Volume 2    5 
  Our study provides evidence that low serum HDL-C is 
independently associated with increased postmenopausal 
breast cancer risk among women with breast cancer. These 
findings suggest an interaction between metabolic distur-
bances (i.e., overweight or obesity and low serum HDL-C) in 
postmenopausal breast carcinogenesis. Probably, after 
menopause, bioavailable estrogens formed in adipose tissue 
by the aromatization of androgens are a major stimulus for 
breast carcinogenesis [32]. Because low HDL-C is related to 
increased levels of several cancer-promoting hormones (e.g., 
androgens, estrogens, insulin, and IGF-I), the observed asso-
ciation may reflect the relative importance and mutual de-
pendence of different disease pathways in malignant breast 
tumours after menopause. Thus, HDL-C is a potential 
marker of postmenopausal breast cancer risk that could pro-
vide a means for identifying women at higher risk who may 
be candidates for preventive intervention in the future. 
  Most recently, in a large cohort of 38.823 women, low 
serum high density lipoprotein cholesterol, described by the 
authors as a part of the metabolic syndrome, was associated 
with increased postmenopausal breast cancer risk [33]. 
  This finding has not been reported in any other situation; 
the only possible explanation is that the tumoral tissue binds 
more insulin than do normal tissues. Guastamacchia et al. 
reported an increase in insulin receptors in malignant tu-
moral tissues [10]. A comprehensive review of insulin and 
cancer risk is beyond the scope of this report. And our hy-
pothesis is that this was responsible for the apparently para-
doxical findings of increased insulin production and lower 
serum levels of insulin. Although not without controversy, 
the preponderance of studies suggest that insulin may influ-
ence cancers that are more commonly seen in Western popu-
lation [34,35]. These authors also suggested that the in-
creased insulin uptake in tumoral tissue might trigger 
mechanisms of cell growth [36,37]. 
 Hankinson  et al. reported an interesting finding of a posi-
tive relation between the concentration of circulating IGF-I 
and risk of breast cancer in premenopausal women with re-
spect to hormone-replacement therapy in postmenopausal 
women [13].  
  The changes in metabolic and endocrine variables in pa-
tients with breast cancer simulate the pattern of changes in 
subjects on a carbohydrate-rich diet, which leads to more or 
less prolonged increase in postprandial serum glucose con-
centrations. This would account for the elevated basal serum 
concentration of glucose in postmenopausal women, and the 
increased Hb1Ac levels in both pre- and postmenopausal 
subjects. This relative hyperglycaemia increases pancreatic 
insulin production, as shown by the increase in C-peptide 
(secreted at equimolar concentrations with insulin) in both 
patient subgroups. Excess insulin subsequently disappears 
from circulation, possibly because of uptake by insulin re-
ceptors in the tumoral tissue [38]. Insulin per se is a tumoral 
growth factor and may stimulate other cellular growth fac-
tors [39]. The link between postmenopausal overweight 
women and breast cancer could be mediated through hyper-
insulinemia [40].  
  The increase in serum total cholesterol in our pre- and 
postmenopausal patients also parallels the increase caused by 
a hypercaloric diet. In addition, postmenopausal women with 
breast cancer had a significantly greater BMI than their con-
trol subgroup, the difference approaching significance in 
premenopausal women with and without cancer. One possi-
ble explaination for the smaller difference between the latter 
subgroups is that women who are less overweight may have 
been physically more active.  
  Serum selenium concentration is thought to reflect die-
tary selenium intake. Like other authors, we found signifi-
cantly lower serum levels of this mineral in patients than in 
controls [19]. We do not agree with (pre- and postmeno-
pausal women) the current opinion on this subject and are 
conducting a clinical and experimental research on the sub-
ject [41]. 
  Triglyceride levels were higher, and HDL-c, levels 
lower, in both pre- and postmenopausal patients than in con-
trols; these differences were statistically significant (p<0.05). 
However, the postmenopausal women with cancer had sig-
nificantly (p<0.05) higher LDL-c than controls.  
  We have proposed the hypothesis that the metabolic pro-
file can be used to identify clinical cases of breast cancer in 
the general population (diagnosis). This is of particular im-
portance for premenopausal women, for whom there is no 
reliable method of early diagnosis. Confirmation of a rela-
tionship of breast cancer risk hyperinsulinemia or with 
plasma IGF-I levels, could open up new perspectives to be 
used in primary prevention, as a normal reference pattern, 
moreover, data from the metabolic profile can be used to 
elaborate a mathematical model of breast carcinogenesis, or 
the use of certain chemopreventive drugs.  
  In conclusion, our findings, if confirmed, have several 
practical implications. Many questions remain to be an-
swered and systematic research should be aimed at clarifying 
the points summarized below 1). We do not yet know 
whether the metabolic alterations described here precede 
breast cancer or appear as a consequence of this disease. 
Moreover, we have yet to determine whether these altera-
tions are reversible 2). It remains to be shown whether meta-
bolic screening and mathematical treatment of the data can 
detect breast cancer in a high risk population before the dis-
ease appears 3). We do not know whether our method is able 
to rule or diagnose breast cancer in premenopausal women 
when the results of mammography are inconclusive 4). The 
effectiveness of our approach needs to be compared with 
mammography, and the performance of both can be assessed 
against the gold standard of histological findings 5). The 
metabolic-endocrine profile could be used to establish nor-
mal reference values in dietetic programs of primary preven-
tion. The lack of target values has meant that programs 
aimed at normalizing the metabolic profile have thus far had 
only limited success 6). We do not know whether the meta-
bolic alterations induce activation oncogenes and play a role 
in the growth of breast cancer 7). Identifying the factors 
which affect these biomarkers is of particular interest as sub-
jects at increased risk could benefit from lifestyle changes, 
and/or chemoprevention intervention. 
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